New Eye Injection Could Cut AMD Treatment to Once a Year

Imagine needing an injection in your eye every single month just to keep your sight. For millions of Americans with age-related macular degeneration, that uncomfortable reality could soon become a thing of the past.

Researchers at UMass Chan Medical School have developed a new gene-silencing therapy that could transform AMD treatment from a monthly burden into a simple once or twice yearly procedure. The breakthrough uses a specially designed molecule called siRNA to target the root causes of vision loss rather than just treating symptoms.

AMD affects roughly 18.5 million Americans over 40, making it the leading cause of visual impairment in older adults. Current treatments require frequent eye injections that many patients describe as stressful and painful, creating challenges with transportation, scheduling, and quality of life.

Dr. Claudio Punzo and his team discovered they could use the therapy to silence a specific gene called S6K1, which helps reverse damage and clear fatty buildup in the eye's connective tissue. This approach works by improving the health of retinal pigment epithelium cells, essentially giving them a healthier "diet" that helps them function better and stops disease progression.

The therapy directly targets photoreceptor cells and remains stable and active in the eye for six months to a year after just one injection. This means patients could go from 12 eye injections per year down to just one or two, dramatically reducing the physical and emotional toll of treatment.

Why This Inspires

What makes this discovery particularly exciting is that it addresses both major forms of AMD: the slow-progressing dry version and the more aggressive wet version that can cause rapid vision loss. About 20 percent of early-stage patients eventually progress to advanced stages that threaten their ability to read, drive, or recognize loved ones.

Dr. Anastasia Khvorova, who led the RNA therapeutics work, explains that protecting these light-sensing cells helps patients maintain independence in their daily lives. The collaboration between disease experts and RNA specialists shows how teamwork in science can create solutions that seemed impossible just years ago.

The research team has already founded Trinetra Therapeutics to bring this innovation from the laboratory to patients. They're finalizing technology licensing and raising funds to begin clinical trials that could make this treatment available within the coming years.

For the 1.5 million Americans living with late-stage AMD, this breakthrough represents more than just fewer doctor visits—it's hope for preserving the precious gift of sight.